Close Menu

single-cell genomics

BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.

Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.